Lenacapavir, a potent first-in-class inhibitor of HIV-1 capsid function, is in development for treatment and prevention of HIV-1 infection. Dr Onyema Ogbuagu (Yale School of Medicine, New Haven, CT, USA) discusses the ongoing phase 2/3 CAPELLA study, investigating lenacapavir in combination with an optimized background regimen treatment-experienced people with HIV-1, with multidrug-resistance and ongoing viremia.
The abstract entitled: ‘Long-Acting Lenacapavir in People with Multidrug Resistant HIV-1: Week 52 Results’ (Abstract #496) was presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2022 (Virtual), 12-16 February 2022.
- What are the unmet needs of people living with HIV infection? (0:14)
- What is the mechanism of action of lenacapavir and what are its potential advantages over existing HIV therapies? (1:21)
- What were the aims, methodology and findings of the CAPELLA trial? (3:02)
- What will be the next steps in the clinical development of lenacapavir in this indication? (7:57)
Disclosures: Onyema Ogbuagu is on advisory boards for Gilead Sciences and ViiV Healthcare and a speaker’s Bureau participant for Gilead Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of CROI 2022.
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Christoph Boesecke: Impact of COVID-19 on the treatment of patients living with HIV
Key clinical highlights in HIV infection are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Christoph Boesecke (Infectious Diseases Specialist, Senior Lecturer, University of Bonn, Bonn, Germany). He discusses the delays caused by the COVID-19 pandemic and the impact that has had on the treatment of patients living with HIV. He also […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!